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Abstract
Background: Sub-Saharan Africa has a high prevalence of hepatitis B virus (HBV) infections. Health care workers (HCWs)
are at high risk of contracting HBV infection through their occupation. Vaccination of HCWs against HBV is standard
practice in many countries, but is often not implemented in resource-poor settings. We aimed with this cross-sectional
study to determine HBV prevalence, HCW vaccination status, and the risk factors for HCWs contracting HBV infection in
Tanzania.
Methods: We enrolled 600 HCWs from a tertiary Tanzanian hospital. Their demographics, medical histories, HBV
vaccination details and risk factors for contracting blood-borne infections were collected using a standardized
questionnaire. Serum samples were tested for HBV and hepatitis C virus (HCV) markers by ELISA techniques, PCR and
an anti-HBs rapid test. HCWs were divided in two subgroups: those at risk of contracting HBV (rHCW 79.2 %) via
exposure to potentially infectious materials, and those considered not at risk of contracting HBV (nrHCW, 20.8 %).
Results: The overall prevalence of chronic HBV infection (HBsAg+, anti-HBc+, anti-HBs-) was 7.0 % (42/598). Chronic HBV
infection was found in 7.4 % of rHCW versus 5.6 % of nrHCW (p-value = 0.484). HCWs susceptible to HBV (HBsAg-, anti-
HBc-, anti-HBs-) comprised 31.3 %. HBV immunity achieved either by healed HBV infection (HBsAg-, anti-HBc+, anti-HBs+)
or by vaccination (HBsAg-, anti-HBc-, anti-HBs+) comprised 36.5 % and 20.2 %, respectively. 4.8 % of participants had
indeterminate results (HBsAg-, anti-HBc+, anti-HBc-IgM-, anti-HBs-). Only 77.1 % of HCWs who received a full vaccination
course had an anti-HBs titer >10 ml/U. An anti-HBs point-of-care test was 80.7 % sensitive and 96.9 % specific. There was a
significantly higher risk for contracting HBV (anti-HBc+) among those HCW at occupational risk (rHCW) of older age (odds
ratios (OR) in rHCW 3.297, p < 0.0001 vs. nrHCW 1.385, p = 0.606) and among those HCW being employed more than
11 years (OR 2.51, p< 0.0001***). HCV prevalence was low (HCV antibodies 1.2 % and HCV-RNA 0.3 %).
Conclusions: Chronic HBV infection is common among Tanzanian HCWs. One third of HCWs were susceptible to
HBV infection, highlighting the need for vaccination. Due to high prevalence of naturally acquired immunity against
HBV pre-testing might be a useful tool to identify susceptible individuals.
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Background
Worldwide, more than 2 billion people are infected with
hepatitis B virus (HBV). Of these, 240 million are
chronic carriers of HBV and are at risk of death from
acute fulminant liver disease, liver cirrhosis or hepatocel-
lular carcinoma (HCC). The World Health Organization
(WHO) has stated that the prevalence of hepatitis B is
highest in sub-Saharan Africa and East Asia, and they
estimate that between 5–10 % of the adult population
are chronically infected [1]. Currently, several drugs like
tenofovir and entecavir have been approved in industri-
alized countries for the therapy of chronic HBV infection
according to established guidelines from professional
medical organizations [2]. Antiviral treatment of chronic
hepatitis B infection significantly delays the progression
of cirrhosis, reduces the incidence of HCC and improves
long-term survival [3]. However, in many resource-
constrained settings, including Tanzania, implementation
of this treatment has not occurred.
The lack of treatment opportunities in resource-
constrained settings makes prevention of HBV infection
crucial. In countries with high HBV prevalence, most
HBV transmission occurs already during childhood;
however, a significant proportion of people remains sus-
ceptible to HBV and is, therefore, at risk of contracting
the virus during their adult age [4, 5].
Hepatitis B is an important occupational hazard for
health care workers (HCW) [1]. In some studies, HCWs
have been shown to have an up to four-fold increased risk
of acquiring HBV infection [4, 5]. The main risk factor to
contract HBV infection for HCWs is direct contact with
infectious material, especially HBV-infected blood or via
a needle stick injury with HBV-contaminated body
fluids [6]. In particular, recapping of hollow-bore needles
appears to increase the risk of needle stick injuries [7].
Other studies have reported a lack of awareness of HBV
among HCWs; consequently, proper precautions (e.g., use
of disposable gloves) against blood-borne infections are
lacking in these workers [8]. This observation is consistent
with other studies demonstrating that untrained individ-
uals are more likely to be exposed to HBV infection [5, 9].
Preventive vaccination against hepatitis B for hospital
staff is standard in many countries, but is still not
implemented in many resources-poor settings [10, 11].
There have been reports of weak immune responses to
HBV vaccination caused by, for example, diabetes or a
current viral infection [12–14]. Therefore the WHO rec-
ommends to monitor immune responses to the vaccine
in addition to compulsory vaccination of HCWs [15].
In Tanzania, the prevalence of acute or chronic HBV
infection among blood donors or adults in Dar es
Salaam, Tanzania, was found to be 8.8 % [16, 17]. and
6 %, respectively. Furthermore, a study conducted on
women in a rural area of north-eastern Tanzania found
that previous contact with HBV was common, with 74 %
of them being HBV-positive as defined by anti-hepatitis
B core antibody (anti-HBc) detection [18]. The high
prevalence of hepatitis B in Tanzania poses not only a
risk to HCWs, but also to non-immune patients who
risk being infected by a HCW with chronic hepatitis B
infection. This is especially applicable to situations
involving invasive medical procedures like surgery [19].
To date, there have not been any reports in the scientific
literature on HBV infection and HBV immune status in
Tanzanian HCWs. Studies on the prevalence of chronic
hepatitis B and C in HCWs from other sub-Saharan
African countries are scanty. Kateera et al. reported a
prevalence of 2.9 % chronic hepatitis B infection, indi-
cated by positive HBsAg, and 1.3 % anti-HCV-positivity
among tertiary hospital employees in Rwanda [20].
Ziraba et al. found chronic hepatitis B infection in 8.1 %
of the HCWs in a central teaching hospital in Uganda
[5]. In Nigerian healthcare workers a HBsAG-prevalence
of 13 % was reported by Ola et al. [21]. Apparently there
are considerable differences in the rate of chronic HBV-
infection among HCWs in sub-Saharan Africa.
With the assumption that the prevalence of hepatitis B
in HCWs will be at least as high as in the general
population, about 30 % of HCWs remain susceptible to
hepatitis B. Non-immune HCWs have a high risk of
contracting an infection at the place of work and would
benefit from vaccination against HBV therefore.
There are no national recommendations or vaccin-
ation program against HBV for HCWs in Tanzania.
However, in 2002 [22] Tanzania implemented the WHO
policy of general HBV vaccination for children as part of
the extended program on immunization (known as EPI).
According to notified data, a vaccination coverage of
91 % of 1-year-old children was achieved in 2013 [23].
A limited national health budget dictates that the
most cost-effective strategy should be found allowing to
implement preventive HBV vaccination for hospital
personnel at risk. Such a strategy should consider the
high rate of naturally acquired HBV infection among
adults in endemic countries [6]. To distinguish immune
HCWs from those who are HBV susceptible, laboratory
tests are essential. Since conventional HBV serology is
costly and often not available in resource-poor settings,
cheaper alternatives need to be found. An expanding
range of point-of-care tests for infectious diseases in-
cluding HBV offer logistical advantages at low cost [24]
and with a sensitivity and specificity comparable to
standard methods.
An accurate point-of-care-test for hepatitis B surface
antibodies (anti-HBs) could identify those HCWs who
are already immune and do not need to be vaccinated
therefore. Taking the comparatively high cost of the
HBV vaccine itself and the logistical costs for the three
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required vaccinations into account, this approach should
be more cost-effective than an untargeted vaccination
program. Here, we aimed to provide data on the preva-
lence of acquired immunity against HBV, HCV and
chronic infection with these viruses in HCWs in a ter-
tiary hospital in Tanzania. The secondary objectives were
the risk of infection for HCWs at work over time, their
vaccination status, and the performance of a commercial
anti-HBs point-of-care-test for use prior to vaccination.
Methods
Study design and setting
This hospital-based study was conducted in 2012 at the
Bugando Medical Centre (BMC) in Mwanza, Tanzania
and used a cross-sectional design. BMC is a referral and
teaching hospital with a 1000 bed capacity serving a
population of about 13 million people in north-western
Tanzania. The hospital engages about 1400 employees in
different professions.
Participants and samples
The study enrolled 600 HCWs aged ≥16 years. In 598 of
the enrolled participants a complete data set was avail-
able for analysis. The study was announced within the
hospital by poster, blackboard, presentations in the lec-
ture hall and oral announcement. The participation was
voluntary and 600 participants were enrolled consecu-
tively until the desired number of participants was met.
The questionnaire was prepared taking into account the
most common professions within the hospital setting.
The questionnaire did not include questions concerning
sexual behavior as this was considered culturally inappro-
priate in the study setting.
Eligible were employees of the hospital of Tanzanian
origin. Medical students and nursing students were
included as they have regular duties in patient care.
Expatriates were excluded from the study.
After giving informed consent, a standardized ques-
tionnaire was used to collect information on demo-
graphics, medical history, profession and the HBV
immunization status of all the participants. The language
of the interview was English or Swahili according to the
preference of the participant. For one sub-analysis,
the HCWs were divided into two subgroups by their
profession. Subgroup 1.A: At occupational risk HCWs
(rHCWs) comprising medical doctors, medical students,
nurses, nursing students, laboratory personnel and
cleaning personnel who are frequently exposed to infec-
tious materials such as used needles. Subgroup 2.A:
Not-at-occupational risk HCWs (nrHCWs) comprising
administration staff, technical service staff and allied
health sciences staff. An additional sub-analysis was
conducted on a subgroup classified by exposure to nee-
dlestick injury, surgery, blood transfusion, intravenous
(i.v.) drug use, intramuscular (i.m.)/i.v. injection; this
subgroup was compared to the non-exposed study par-
ticipants, regardless of their profession.
From each participant, 14 ml of whole blood was
collected into two serum sampling tubes for serological
analysis. The samples were centrifuged for 3 min at
1650 g and the serum was stored in cryovials at −20 °C.
For shipment the samples were packed in a special
insulation box to maintain a temperature of −20 °C.
Ethical issues
The study was approved by the CUHAS/BMC Research
Committee (BREC) joint ethics review board (Research
Clearance Certificate: BREC/001/06/2012). All partici-
pants signed an informed consent form that covered
sample analysis for HBV and HCV. Testing for HIV was
explicitly excluded as it was assumed to interfere with
the willingness to participate in the study. Each partici-
pant received a study number. No personal data was
recorded at any time. The individual test results were
made available to the hospital in a sealed envelope la-
belled with the specific study number. Each participant
was able to collect his letter anonymously, containing
the laboratory results and their interpretation. In case of
findings indicating a chronic Hepatitis B the participant
was advised to seek medical care for further evaluation.
Benefit for the study participant
Although currently no antiviral treatment is licensed for
chronic hepatitis B infection in Tanzania knowledge of
the hepatitis B status is of benefit for the patient, as he
is able to undergo further monitoring and evaluation. In
addition, it allows family members and potential sexual
partners to be vaccinated. In case of women of child-
bearing age prevention of mother-to-child transmission
is possible. Those participants with significant anti-HBs
titers were reassured of their Hepatitis B immunity,
those without previous infection were advised to be
vaccinated against HBV. These aspects were carefully
considered by the ethical board of the hospital.
HBV and HCV analyses
All serological analyses were performed in Germany
after transfer of the samples from Tanzania. Serum
samples were available for analysis in 598 of 600
participants. All serum samples were tested for HBs-
antigen, anti-HBc antibodies and quantitative anti-HBs-
antibodies. In addition, HBs-antigen-positive samples
were tested for anti-HBc IgM antibodies, HBe-antigen
and anti-HBe antibodies. The following test kits were
used for HBV serology: Enzygnost HBsAg 6.0 (Siemens
Healthcare, Marburg, Germany), Enzygnost anti-HBc
monoclonal (Siemens), Architect Anti-HBs (Abbott,
Wiesbaden, Germany), and Architect Anti-HBc-IgM. All
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598 serum samples were screened for hepatitis C anti-
bodies. Anti-HCV-positive samples were analyzed by
PCR for HCV RNA. HCV antibodies were identified
using the Architect Anti-HCV assay (Abbott). In
addition, 592 serum samples were tested with further
anti-HBs antibody test (Hepatitis B antibody test no.
BSB3120001, SureScreen Diagnostics, Derby, Great Brit-
ain), which was an easy-to-use point-of-care test in cas-
sette format. The test utilizes a double antigen sandwich
system and detects anti-HBs levels as low as 10 U/mL in
whole blood, serum or plasma.
Statistical analysis
Data were entered into a Microsoft Excel database.
Statistical analyses were performed using IBM SPSS
Version 18 software and GraphPad Prism version 6.01
for Windows, GraphPad Software, La Jolla California
USA, http://www.graphpad.com/scientific-software/prism/.
Chi-square and Fisher exact tests were used to assess
associations between categorical variables.
Results
Patient characteristics
Four age groups were defined: 16–30 years (198/33.1 %),
31–40 years (178/29.8 %), 41–50 years (120/20.1 %) and
51–65 years (102/17.1 %). Among all participants, 360
(60.2 %) were female. Out of the study participants 473
(79.2 %) were stratified as rHCWs and 125 (20.8 %) as
nrHCWs according to the questionnaire.
HBV and HCV prevalence
The overall prevalence of chronic HBV infection
(HBsAg+, anti-HBc+, anti-HBs-) was 7.0 % (42/598).
Chronic HBV infection was found in 7.4 % of rHCWs
versus 5.6 % of nrHCWs, with no statistical significance
difference between these groups (p-value = 0.484). Those
still susceptible to HBV infection comprised 31.3 % of
the HCWs (HBsAg-, anti-HBc-, anti-HBs-). HBV im-
munity achieved in HCWs either by healed HBV
infection (HBsAg-, anti-HBc+, anti-HBs+) or by vaccin-
ation (HBsAg-, anti-HBc-, anti-HBs+) was found in
36.5 % and in 20.2 % respectively. A serum marker con-
stellation considered as healing HBV infection (HBsAg+,
anti-HBc+, anti-HBs+) was found in one participant
(0.2 %). We found that 29 participants (4.8 %) had inde-
terminate results (HBsAg-, anti-HBc+, anti-HBc-IgM-,
anti-HBs-) with isolated anti-HBc positivity caused by
long-standing resolved infections with low anti-HBs
titers or current infections with low HBsAg titers
(Table 1 and Fig. 1).
HCV prevalence was low, with HCV antibodies of
1.2 % and HCV RNA of 0.3 %. There was no statistically
significant difference between the rHCW and nrHCW
groups (p-value HCV-Antibodies: 0.668, HCV-RNA:
0.309), and no co-infections of HBV and HCV. Due to
the low prevalence of HCV-infection no further statis-
tical analyses were performed.
HBV vaccinations in HCWs
Out of the 598 HCWs, 380 (63.5 %) stated in their ques-
tionnaires that they had been vaccinated against HBV.
Also, 292 (48.8 %) of them had received three doses of
the vaccine in the last 10 years, while 60 (10 %) had re-
ceived two vaccinations, and 27 (4.5 %) only one vaccin-
ation. One participant was vaccinated more than
10 years ago. In the group vaccinated three times within
the last 10 years, anti-HBs positive results were found in
225 (77.1 %) of them. No laboratory confirmation of suc-
cessful vaccination was done in the past.
Point-of-care rapid testing
Sera analyzed with the point-of-care SureScreen Rapid
Test Cassette were positive in 272 of 337 Architect anti-
HBs positive samples (sensitivity 80.7 %). The cut off
limit of Architect anti-HBs is 10 IU/L. Eight samples of
255 (3.1 %) Architect anti-HBs negative tests were posi-
tive by SureScreen Rapid Test (specificity 96.9 %). Six
Table 1 HBV infection status of HCWs from a Tanzanian tertiary hospital




+ + <10 Chronic infection 42/7.0 % 35/7.4 % 7/5.6 % 0.484
- - <10 Susceptible 187/31.3 % 144/30.4 % 43/34.4 % 0.498
- + >10 Immune after healed infection 218/36.5 % 171/36.2 % 47/37.6 % 0.765
- - >10 Immune after vaccination 121/20.2 % 99/20.9 % 22/34.4 % 0.432
+ + >10 Healing infection 1/0.2 % 1/0.2 % — –
- + <10 Indeterminate: Long-standing resolved infection with low
anti-HBs; Current infection with low HBsAg
29/4.8 % 23/4.9 % 6/4.8 % 0.977
HBV hepatitis B virus, HCW health care worker
Subgroups: rHCWs who were frequently exposed to infectious materials and therefore at risk of contracting HBV infection, and nrHCWs who were considered not
to be at risk of contracting HBV infection
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tests were not done because of a lack of material
(Table 2).
HBV risk factors
Some risk factors were found to be significantly associ-
ated with chronic hepatitis B infection (HBsAg+) and
the risk to contract HBV-infection (anti-HBc+) at a 5 %
level of significance (Table 3). There was no significant
difference for contracting HBV (anti-HBc+) between
males and females (OR females 0.8897; p = 0.5044), but
females had a statistically significant lower risk to
develop chronic infection (HBsAg+) (OR females 0.4484;
p = 0.0146).
A significantly higher risk for contracting HBV was
identified by estimating the anti-HBc odds ratios in the
different age groups. The results showed a statistically
significant correlation between age of the HCW and ac-
quisition of markers of HBV. The odds ratio in 51–65
year-old group of all HCW compared to 16–30 year-olds
was 2.766 (p = <0.0001). This result is consistent with
the fact, that the odds ratio in participants with a work-
ing duration of more than 11 years compared to those
with a working duration of less than 5 years was 2.511
(p = <0.0001).When separated into the two subgroups of
HCW at occupational risk and those not at occupational
risk the odds ratio for contracting HBV (anti-HBc+) in
the 51–65 year-old group compared to 16–30 year-olds
in the rHCW group was 3.297 (p < 0.0001) versus
nrHCW 1.385(p = 0.606) (Fig. 2). Overall, we found an
increase of anti-HBc positivity in HCWs with risk fac-
tors (49.6 %) versus individuals without risk factors
(34.2 %; p = 0.065, Chi square test) but there was no
statistically significant difference (Fig. 3).
Discussion
This study revealed a high burden of HBV infection in
HCWs in Tanzania. The overall prevalence of chronic
HBV infection (HBsAg positivity) among HCWs in a
tertiary hospital in the northern part of Tanzania was
7.0 %. Immunity (anti-HBs positivity) was present in
56.9 % of workers but 31.3 % of them were still suscep-
tible to HBV infection. Immunity against HBV was
achieved via a healed infection in 36.5 % of the HCWs
or via vaccination in 20.2 % of this group. The findings
from a similar study conducted among HCWs in
Uganda, which borders the northern part of Tanzania,
Fig. 1 HBV- status in HCWs in Tanzania. Prevalence of chronic HBV infection (HBsAg+, anti-HBc+, anti-HBs-), HBV immunity achieved by healed
HBV infection (HBsAg-, anti-HBc+, anti-HBs+) or by vaccination (HBsAg-, anti-HBc-, anti-HBs+), indeterminate result (HBsAg-, anti-HBc+, anti-HBs-)
and HBV susceptibility (HBsAg-, anti-HBc-, anti-HBs-) in Tanzanian HCWs in a tertiary hospital as determined by HBV serology. HBV: hepatitis B virus;
HCWs: health care workers
Table 2 Sensitivity and Specificity of Surescreen anti-HBs Rapid test compared to Architect anti-HBs
Architect anti-HBs negative <10 IU/L Architect anti-HBs positive >10 IU/L
Rapid test anti-HBs negative 247 65
Rapid test anti-HBs positive 8 272
Total 255 337
Specificity: anti-HBs10 = 247/255 = 96.9 %
Sensitivity: anti-HBs10 = 272/337 = 80.7 %
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found a comparable prevalence of current HBV infection
(8.1 %) but a higher prevalence of HBV susceptibility
(48.9 %) [5].
The proportion of HCWs who achieved immunity due
to healed infection with HBV in this study (36.5 %) was
higher than that of a different study on outpatients
(25.3 %) [25] in Tanzania, suggesting that HCWs have a
high risk of becoming infected with HBV through their
occupation. Additionally, we found a greater than 3-fold
higher risk for HCWs to acquire an infection with HBV
during their life, especially when they are on occupa-
tional risk e.g. handling blood and needles (odds ratio
3.297, p < 0.0001).
The study found a significantly higher rate of HBV ex-
posure in older HCW than in younger ones. This could
be explained by various reasons. One explanation could
Table 3 Risk factors for contracting hepatitis B virus and current HBV infection
Variables Current HBV Infection (HBsAg +) Contracting HBV (Anti HBc+)
Odds ratio P–value Odds ratio P–value
Gender (Ref = Male)
Female 0.45 [0.24–0.84] 0.0146* 0.89 [0.64–1.24] 0.5044
Age (Ref =16–30)
31–40 0.91 [0.43–1.90] 0.8526 1.43 [0.95–2.16] 0.0939
41–50 0.76 [0.32–1.82] 0.6687 1.75 [1.06–2.88] 0.0304*
51–65 0.43 [0.14–1.33] 0.1574 2.77 [1.69–4.53] <0.0001***
Work duration (Ref = 0–5)
6–10 1.59 [0.74–3.42] 0.2892 1.45 [0.92–2.28] 0.1286
>11 0.74 [0.35–1.58] 0.4650 2.51 [1.74–3.63] <0.0001***
Profession (Ref = Administration)
Medical Doctors (Surgeons, Physicians, Students) 3.69 [0.81–16.86] 0.0923 1.56 [0.87–2.82] 0.1767
Nursing staff 2.41 [0.54–10.77] 0.3816 1.00 [0.58–1.70] 1
Laboratory personnel 1.29 [0.06–28.71] 1 1.54 [0.40–5.96] 0.7370
Allied Sciences 1.34 [0.12–15.44] 1 0.64 [0.26–1.62] 0.3674
Technical Services 5.15 [0.89–29.87] 0.0667 1.18 [0.50–2.78] 0.8275
Cleaning Staff 2.70 [0.54–13.40] 0.3042 1.52 [0.81–2.84] 0.2057
Risk factors (Ref = Yes)
Blood transfusion 0.44 [0.10–1.88] 0.4156 1.02 [0.59–1.76] 1
Operation 0.97 [0.48–1.99] 1 1.08 [0.75–1.55] 0.7103
i.m./i.v.drug administration 1.47 [0.44–4.90] 0.7883 1.50 [0.86–2.61] 0.1677
Needle stick injury 0.96 [0.50–1.84] 1 1.12 [0.80–1.56] 0.5504
Fig. 2 Risk of HCWs contracting HBV by age. Risk of contracting HBV (based on anti-HBc-positivity tests) by age group in health care workers at
occupational risk (rHCW) or those not at occupational risk (nrHCW). Data are shown as a risk factor odds ratio table. HBV: hepatitis B virus
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be that there is a more or less constant risk of exposure
during life time and therefore the Hepatitis B prevalence
increases with age. We cannot rule out, that the risk of
transmission might have changed over time due to in-
creased awareness and precautions like wearing of gloves
and use of safety needles.
On the other hand the finding, that long occupational
exposure in healthcare services increases the risk of ac-
quiring HBV infection, is consistent with other studies
[5, 26, 27]. Up to now, Tanzania has not performed a
controlled nationwide vaccination campaign against
hepatitis B in high risk groups like HCW’s [28]. In the
past, the special setting of this tertiary health care facility
made it possible to start decentralized HBV vaccination
programs in HCWs supported by donations. Hence, the
proportion of HCWs (20.2 %) who received full vaccina-
tions is higher than in other studies [5, 25]. But the
vaccination programs conducted thus far have been of
doubtful efficacy. Indeed, 63.5 % of the HCWs stated in
their questionnaires that they were vaccinated against
HBV, but only 48.8 % of the vaccinated had received
three shots within the last 10 years. Within this group,
immunity to HBV could be demonstrated in only 77.1 %
by detection of anti-HBs antibodies. This leaves 22.9 %
of the remaining HCWs in doubtful protection despite
feeling well protected. Their doubtful status of immunity
remains unnoticed without laboratory confirmation of a
sufficient antibody titer against the virus.
Even though in resource-limited settings most HBV
infections occur perinatal or secondarily during early
childhood, there is still a high risk of HCWs becoming
infected via occupational exposure to the virus. In HBV-
endemic developing countries where people have high
rates of natural immunity, the provision of universal
HBV vaccination for HCWs is often discussed be-
cause of questionable cost effectiveness of this pre-
ventive strategy [6, 29]. It can be assumed, that an
approach avoiding unnecessary vaccinations could re-
duce the costs of a vaccination program. Hence, intro-
duction of a point-of-care test for anti-HBs in a
pre-vaccination screening phase for HCWs could be
cost-effective. Use of such a test could reduce the num-
ber of HCWs requiring vaccination, avoid unnecessary
vaccinations and save vaccine for individuals already
being immune. The SureScreen anti-HBsAb-Test used
in this study had a sensitivity of 80.7 % and a specificity
of 96.9 %. Using this rapid diagnostic test, 46.8 % of the
participants were identified, for various reasons, as
being immune to HBV; hence, these HCWs will require
no further vaccinations against HBV. For the above
reasons, pretesting of the HBV status of HCWs could be
worthwhile before implementing a nationwide vaccin-
ation program for HCWs, providing a test of high sensi-
tivity and specificity is available. The test used in this
study has the limitation, that the detected specificity is
low. Aside from the existing policy in Tanzania on injec-
tion safety in health care settings, use of auto-disposable
syringes and better safety awareness concerning HBV as
an infectious agent are crucial to the prevention of
blood-borne infections.
Hepatitis C
Data concerning HCV infection in Sub-Saharan Africa
are scanty. Therefore we screened the samples also
for HCV antibodies. We found an HCV-antibody
prevalence of 1.2 % with only 2 chronic HCV infec-
tions demonstrated by RNA detection.
Compared to our results in the Democratic Repub-
lic of Congo 13.7 % of the samples were seropositive
for HCV but only 3.7 % were viraemic [29]. Other
African studies from Nigeria and Angola showed rates
of HCV seroprevalence (anti-HCV+) of 12.8 % and
8.1 % [30, 31].
Limitations of the study
Voluntary participation in a study has always limitations
resulting from a recruitment bias. Our study might not
reflect a representative sample of the hospital staff.
All information concerning previous vaccinations was
obtained by questionnaire without validation by vac-
cination records. Concerning the efficacy of Hepatitis
B vaccination a recall bias of the participants needs
to be considered concerning the number and type of
vaccinations.
Fig. 3 Exposure to HBV in Tanzanian HCWs with and without
additional risk factors. Anti-HBc positivity (contact with HBV) in
HCWs with additional risk factors (49.6 %) versus professionals
without additional risk factors (34.2 %; p = 0.065 Chi square Test).
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Conclusions
We found that the prevalence of chronic HBV infection
and the risk of occupational exposure to HBV among
HCWs were both high in a tertiary hospital in northern
Tanzania. One third of HCWs were found to be susceptible
to HBV infection. This finding highlights the need for HBV
vaccination among HCWs. Currently, protection of HCWs
against HBV in this tertiary hospital is beyond the desired
level because they have not been vaccinated, the vaccine
has failed to induce protection, or they have not received
all three doses. Laboratory confirmation of immunization
success was not conducted. Taking into account the high
prevalence of naturally acquired immunity anti-HBs testing
could avoid unnecessary immunizations. For this purpose
highly sensitive and specific point-of-care tests would be
needed. The cost effectiveness of such an approach should
be analyzed in further studies. The Tanzanian government
recognizes the importance of HBV vaccination for children;
the next step could be to consider adults at risk, such as
HCWs, for a targeted vaccination campaign.
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